New long-term data should help GSK’s Arexvy reinforce its lead among respiratory syncytial virus (RSV) vaccines, though its sales have fallen back under pressure from competitors and narrower US vaccination guidelines.
GSK’s Arexvy Reinforces Its Lead In A Stalling RSV Vaccine Market
Arexvy has become the first RSV vaccine to show it can provide protection over three years – but that might mean lower market uptake than originally expected.
